Clinical Trial Evaluates Hormone Therapy With And Without Zoledronic Acid In Men With Prostate Cancer And Bone Metastases Who Are Treatment-Naïve

Zoledronic acid (ZA) is considered the standard of care to prevent skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases. The question that still remains is when to start the ZA. In a phase III clinical trial a total of 227 men with hormonal treatment-naïve prostate cancer and bone metastases were randomly assigned in a 1:1 ratio to receive zoledronic acid along with ADT (LH-RH analogue + bicalutamide) or ADT alone. After a median follow-up of 41.1 months it was found that in men with hormonal treatment naïve prostate cancer with bone metastases, concurrent use of ZA [...]